Atlas Trials

Hormone Receptor Positive Tumor

31 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Hormone Receptor Positive Tumor

RecordFirmDate
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer (NCT04352777)Duke University2020-09-14
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer (NCT04134884)Kathy Miller2020-04-01
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer (NCT04088110)Fuzhou General Hospital2019-11-01
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (NCT03917082)British Columbia Cancer Agency2019-09-23
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (NCT03910712)Peking Union Medical College Hospital2019-06-01
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (NCT03874325)H. Lee Moffitt Cancer Center and Research Institute2019-04-26
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (NCT03809988)MedSIR2019-04-05
Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA) (NCT04161833)Azienda Ospedaliero-Universitaria Careggi2018-11-01
Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer (NCT03904173)Oslo University Hospital2018-10-29
Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer (NCT03691311)Institut Català d'Oncologia2018-07-05
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer (NCT03407768)University of Saskatchewan2018-07-01
Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line (NCT03462251)iOMEDICO AG2018-05-24
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (NCT03906669)St Vincent's Hospital2018-03-20
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (NCT03409198)Oslo University Hospital2018-01-21
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (NCT02894398)iOMEDICO AG2016-09-06
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (NCT02730923)Centre Leon Berard2016-04-01
Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors (NCT02592083)Thomas Hatschek2015-10-01
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT02441946)Eli Lilly and Company2015-08-01
Dose EScalation Induction of EvERolimus (NCT02387099)GBG Forschungs GmbH2015-05-01
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (NCT01042379)QuantumLeap Healthcare Collaborative2010-03-01

Track Hormone Receptor Positive Tumor automatically

Every clearance here is in the API, with alerts when new ones post.